This HTML5 document contains 116 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1093/ANNONC/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q84539941
rdf:type
wikibase:Item
schema:description
scientific article published on 11 July 2011 artigo científico 2011年学术文章 מאמר מדעי 2011年学术文章 vědecký článek επιστημονικό άρθρο مقالة علمية نشرت في 11 يوليو 2011 artikull shkencor artykuł naukowy wissenschaftlicher Artikel 2011年學術文章 articol științific vedecký článok 2011年學術文章 2011年学术文章 scientific article published on 11 July 2011 artigo científico 2011年学术文章 научна статия scienca artikolo artículo científico publicado en 2011 2011 nî lūn-bûn мақолаи илмӣ 2011年學術文章 wetenschappelijk artikel teaduslik artikkel 2011年學術文章 artikulong pang-agham 2011年学术文章 научни чланак 2011년 논문 artículu científicu tieteellinen artikkeli 2011年の論文 2011年学术文章 vitskapeleg artikkel научни чланак სამეცნიერო სტატია artigo científico artikel ilmiah научная статья 2011 թվականի հուլիսի 11-ին հրատարակված գիտական հոդված ১১ জুলাই ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2011年學術文章 บทความทางวิทยาศาสตร์ videnskabelig artikel udgivet 11. juli 2011 article científic articolo scientifico naučni članak bài báo khoa học наукова стаття, опублікована в липні 2011 scientific article published on 11 July 2011 vitenskapelig artikkel bilimsel makale article scientific article scientifique tudományos cikk vetenskaplig artikel
p:P577
wds:Q84539941-2289323A-403C-4FF4-89FE-912BD715E9C6
wdt:P577
2011-07-11T00:00:00Z
p:P2093
wds:Q84539941-635E111F-EC5C-4675-BC5F-8F5E3621A89C wds:Q84539941-785962CF-39C4-4BD5-A235-0C877097EA6F wds:Q84539941-58C9843D-D67E-4D98-8E3A-69C82C103494 wds:Q84539941-2B9DFD6C-A459-439A-9B00-AD25D46EB9FD wds:Q84539941-ABBAFE97-CACB-4E16-9584-67ECFEB831F5 wds:Q84539941-AF6E89AD-D92C-4304-BA34-40CA49F3AAE0 wds:Q84539941-92A5D23B-B650-41F1-BADD-9870C7ED2447 wds:Q84539941-C659E2BA-5B79-4C72-8A06-4DC8DF0ABE2A wds:Q84539941-E1430FE6-A7E7-4DA9-9F5F-13DAA7596BE8 wds:Q84539941-BFCC5F2A-4F47-4DF2-A0C6-6E26EB58EBB6 wds:Q84539941-8A1D2CCF-AA63-4BA1-A588-9AE7BF7C7A95
wdt:P2093
C Y Muller M Purdy L A Cerilli D Snyder T Bocklage S-J Lee I Rabinowitz R Quinn B Schmit S Eberhardt S Movva
rdfs:label
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen
skos:prefLabel
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen
schema:name
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen
p:P50
wds:Q84539941-974E46A9-FD91-4D94-B57B-1A18AC298271 wds:Q84539941-B08A137D-48F3-4912-B082-CCB3A177D3C6
wdt:P50
wd:Q59161104 wd:Q57065724
p:P1476
wds:Q84539941-A6DD4933-EDC0-499E-AC1F-8CB5C4CB32DA
wdt:P1476
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen
p:P304
wds:Q84539941-B5983CD8-6B9E-42B9-B26F-A9FB20833C5A
wdt:P304
785-790
p:P31
wds:Q84539941-81019735-D7AC-4E2A-A63C-0CE893533468
wdt:P31
wd:Q13442814
p:P921
wds:Q84539941-9E8ECDAD-C325-4CE3-9E65-21C42DC23835 wds:Q84539941-90C30922-0807-418F-B57F-E5A7890EDE4F
wdt:P921
wd:Q420436 wd:Q413299
p:P698
wds:Q84539941-ED966EE1-4928-4BB8-B456-4C2ED5B1D9BA
wdtn:P698
n9:21746804
wdt:P698
21746804
p:P1433
wds:Q84539941-AFB4769C-452A-46BE-B672-5364AD0685C8
wdt:P1433
wd:Q326122
p:P433
wds:Q84539941-9124AA35-3D6F-4705-9487-005560DDB3D7
p:P478
wds:Q84539941-EF8045AF-C3E2-45F3-84BE-451615E73657
wdt:P433
3
wdt:P478
23
p:P356
wds:Q84539941-32B04FDD-7DA4-4A19-9305-5F7BF1FEC4C5
wdtn:P356
n11:MDR299
wdt:P356
10.1093/ANNONC/MDR299